ADPKD New Updates
- Overweight and Obesity and Progression to End-Stage Kidney Disease in Patients with Autosomal Dominant Polycystic Kidney Disease
- Open-label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease Receiving Tolvaptan Kiyotaka Uchiyama et.al. KI Report 2025
- Overview of ADPKD in Pregnancy Ruth E. Campbell et.al. KI Reports 2025
- Assessing Pain in Patients With Polycystic Kidney Disease: Opportunities, Challenges, and Insights Abdou Y. Omorou et.al. KI REPORTS 2024
- Kdigo ADPKD guidelines 2025
Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis. Vijay Ivaturi et.al. Kidney360 5: 996–1001, 2024.
- Prevalence of Renal Neoplasia in Autosomal Dominant Polycystic Kidney Disease: Systematic Review and Meta-Analysis. Anna M. Drake et.al. Nephron 2024;148:457–467.
- Biomarkers of Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Ahmad Ghanem et.al. Kidney International Reports (2024).
Perspectives